Neuroprotective effects of olanzapine on methamphetamine-induced neurotoxicity are associated with an inhibition of hyperthermia and prevention of Bcl-2 decrease in rats

Brain Research

Volumn 1018, Issue 2, 2004, Pages 186-192

  He, Jue ^a   Xu, Haiyun ^a   Yang, Yi ^a   Zhang, Xia ^a   Li, Xin Min ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Bcl 2; Disorders of the nervous system; Hyperthermia; Methamphetamine; Neuroprotective effect; Neuropsychiatric disorders; Olanzapine; Tyrosine hydroxylase

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; GENE PRODUCT; METHAMPHETAMINE; OLANZAPINE; PROTEIN BCL 2; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HYPERTHERMIA; IMMUNOHISTOCHEMISTRY; MALE; MORTALITY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PUTAMEN; RAT;

ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; BENZODIAZEPINES; BRAIN DISEASES; DOPAMINE; FEVER; IMMUNOHISTOCHEMISTRY; MALE; METHAMPHETAMINE; NEOSTRIATUM; NEUROPROTECTIVE AGENTS; NEUROTOXINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; SURVIVAL RATE; TYROSINE 3-MONOOXYGENASE;

EID: 3343019119     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2004.05.060     Document Type: Article

References (56)

1. Abekawa T., Ohmori T., Koyama T. Tolerance to the neurotoxic effect of methamphetamine in rats behaviorally sensitized to methamphetamine or amphetamine. Brain Res. 767:1997;34-44
2. Adams J.M., Cory S. The Bcl-2 protein family: arbiter of cell survival. Science. 281:1998;1322-1326
3. Albers D.S., Sonsalla P.K. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J. Pharmacol. Exp. Ther. 275:1995;1104-1114
4. Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 18:1998;63-101
5. Bai O., Wei Z., Lu W., Bowen R., Keegan D., Li X.-M. Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J. Neurosci. Res. 69:2002;278-283
6. Beasley C.M., Tollefson G.D., Tran P.V. Efficacy of olanzapine: an overview of pivotal clinical trials. J. Clin. Psychiatry. 58:1997;7-12
7. Bisagno V., Ferguson D., Luine V.N. Short toxic methamphetamine schedule impairs object recognition task in male rats. Brain Res. 940:2002;95-101
8. Blessing W.W., Seaman B., Pedersen N.P., Ootsuka Y. Clozapine reverses hyperthermia and sympathetically mediated cutaneous vasoconstriction induced by 3,4-methylenedioxymethamphetamine (ecstasy) in rabbits and rats. J. Neurosci. 23:2003;6385-6391
9. Bowyer J.F., Tank A.W., Newport G.D., Slikker W. Jr., Ali S.F., Holson R.R. The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J. Pharmacol. Exp. Ther. 260:1992;817-824
10. Bowyer J.F., Davies D.L., Schmued L., Broening H.W., Newport G.D., Slikker W., Holson R.R. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J. Pharmacol. Exp. Ther. 268:1994;1571-1580
11. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14:1996;87-96
12. Bymaster F.P., Hemrick-Lueke S.K., Pery K.W., Fuller R.W. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology. 124:1996;87-94
13. Bymaster F.P., Rasmussen K., Calligaro D.O., Nelson D.L., DeLapp N.W., Wong D.T., Moore N.A. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J. Clin. Psychiatry. 58:1997;s28-s62
14. Cadet J.L., Brannock C. Free radicals and pathobiology of brain dopamine systems. Neurochem. Int. 32:1998;117-131
15. Cadet J.L., Ordonez S.V., Ordonez J.V. Methamphetamine induces apoptosis in immortalized neural cells: protection by the proto-oncogene, bcl-2. Synapse. 25:1997;178-184
16. Cadet J.L., Jayanthi S., Deng X. Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J. 17:2003;1775-1788
17. Cubells J.F., Rayport S., Rajendran G., Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14:1994;2260-2271
18. Davidson C., Gow A.J., Lee T.H., Ellinwood E.H. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brains Res. Rev. 36:2001;1-22
19. DeLisi L.E., Sakuma M., Rew W., Kushner M., Hoff A.L., Grimson R. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res. 74:1997;129-140
20. Deng X., Cadet J.L. Methamphetamine-induced apoptosis is attenuated in the striata of copper-zinc superoxide dismutase transgenic mice. Mol. Brain Res. 83:2000;121-124
21. Eisch A.J., Marshall J.F. Methamphetamine neurotoxicity: dissociation of striatal dopamine terminal damage from parietal cortical cell body injury. Synapse. 30:1998;433-445
22. Fukumura M., Cappon G.D., Pu C., Broening H.W., Vorhees C.V. A single dose model of methamphetamine-induced neurotoxicity in rats: effects on neostriatal monoamines and glial fibrillary acidic protein. Brain Res. 806:1998;1-7
23. Fulton B., Goa K.L. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 53:1997;281-298
24. Golembiowska K., Konieczny J., Wolfarth S., Ossowska K. Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats. Neuropharmacology. 45:2003;484-492
25. Goudie A.J., Smith J.A., Robertson A., Cavanagh C. Clozapine as a drug of dependence. Psychopharmacology. 142:1999;369-374
26. He J., Yamada K., Nabeshima T. A role of Fos expression in the CA3 region of the hippocampus in spatial memory formation in rats. Neuropsychopharmacology. 26:2002;259-268
27. Howard S., Bottino C., Brooke S., Cheng E., Giffared R.G., Sapolsky R. Neuroprotective effects of bcl-2 overexpression in hippocampal cultures: interactions with pathways of oxidative damage. J. Neurochem. 83:2002;914-923
28. Imam S.Z., Ali S.F. Selenium, an antioxidant, attenuates methamphetamine-induced dopaminergic toxicity and peroxynitrite generation. Brain Res. 855:2000;186-191
29. Imam S.Z., Itzhak Y., Cadet J.L., Islam F., Slikker W. Jr., Ali S.F. Methamphetamine-induced alteration in striatal p53 and bcl-2 expressions in mice. Mol. Brain Res. 91:2001;174-178
30. Itzhak Y., Ali S.F. The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo. J. Neurochem. 67:1996;1770-1773
31. Jayanthi S., Deng X., Bordelon M., McCoy M.T., Cadet J.L. Methamphetamine causes differential regulation of pro-death and anti-death Bcl-2 genes in the mouse neocortex. FASEB J. 15:2001;1745-1752
32. Kane D.J., Sarafian T.A., Anton R., Hahn H., Gralla E.B., Valentine J.S., Ord T., Bredesen D.E. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science. 262:1993;1274-1277
33. Kita T., Wagner G.C., Nakashima T. Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. J. Pharmacol. Sci. 92:2003;178-195
34. Kluck R.M., Bossy-Wetzel E., Green D.R., Newmeyer D.D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 275:1997;1132-1136
35. Lan K.C., Lin Y.F., Yu F.C., Lin C.S., Chu P. Clinical manifestations and prognostic features of acute methamphetamine intoxication. J. Formos. Med. Assoc. 97:1998;528-533
36. Li X.-M., Chlan-Fourney J., Bennett V., Shrikhande S., Juorio A.V., Keegan D., Qi J., Boulton A.A. Differential effects of Olanzapine on the gene expression of superoxide dismutase and low affinity nerve growth factor receptor. J. Neurosci. Res. 56:1999;72-75
37. Martinou J.C., Dubois-Dauphin M., Staple J.K., Rodriguez I., Frankowski H., Missotten M., Albertini P., Talabot D., Catsicas S., Pietra C., et al. Overexpression of BCL-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. Neuron. 13:1994;1017-1030
38. Ninan I., Kulkarni S.K. Antagonism by pimozide of olanzapine-induced hypothermia. Fundam. Clin. Pharmacol. 13:1999;541-546
39. O'Dell S.J., Weihmuller F.B., Marshall J.F. Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlates with subsequent neurotoxicity. Brain Res. 564:1991;256-260
40. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, London
41. +-induced apoptosis. Eur. J. Neurosci. 17:2003;1563-1570
42. Salmi P., Karlsson T., Ahlenius S. Antagonism by SCH 23390 of clozapine-induced hypothermia in the rat. Eur. J. Pharmacol. 253:1994;67-73
43. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., DeLoore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 124:1996;57-73
44. Schwaninger M., Weisbrod M., Schwab S., Schroder M., Hacke W. Hypothermia induced by atypical neuroleptics. Clin. Neuropharmacol. 21:1998;344-346
45. Seiden L.S., Sabol K.E. Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Res. Monogr. 163:1996;251-276
46. Shimizu S., Narita M., Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature. 399:1999;483-487
47. Susin S.A., Zamzami N., Castedo M., Hirsch T., Marchetti P., Macho A., Daugas E., Geuskens M., Kroemer G. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J. Exp. Med. 184:1996;1331-1341
48. Waddington J.L., O'Callaghan E., Buckley P., Larkin C., Redmond O., Stack J., Ennis J. The age differences of MRI abnormalities in schizophrenia suggest early ventricular enlargement but later prominence of cortical atrophy. Schizophr. Res. 5:1991;188-189
49. Wallace T.L., Gudelsky G.A., Vorhees C.V. Methamphetamine-induced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat. J. Neurosci. 19:1999;9141-9148
50. Wei Z., Bai O., Richardson J.S., Mousseau D.D., Li X.-M. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J. Neurosci. Res. 73:2003;364-368
51. L/S expression and localization. J. Neurosci. Res. 74:2003;942-947
52. Woods B.T., Yurgelun-Todd D., Benes F.M., Frankenburg F.R., Pope H.G., McSparren J. Progressive ventricular enlargement in schizophrenia: comparison to bipolar disorder and correlation with clinical course. Biol. Psychiatry. 27:1990;341-352
53. Wyatt R.J., Henter I.D. The effects of early and sustained intervention on the long-term morbidity of schizophrenia. J. Psychiatr. Res. 32:1998;169-177
54. Xu H., Qing H., Lu W., Keegan D., Richardson J., Chlan-Fourney J., Li X.-M. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci. Lett. 321:2002;65-68
55. Xu H., Richardson J.S., Li X.-M. Dose-related effects of chronic antidepressants on neuroprotective proteins BDNF, Bcl-2, and Cu/Zn-SOD in rat hippocampus. Neuropsychopharmacology. 28:2003;53-62
56. Zhong L.T., Sarafian T., Kane D.J., Charles A.C., Mah S.P., Edwards R.H., Bredesen D.E. BCL-2 inhibits death of central neural cells induced by multiple agents. Proc. Natl. Acad. Sci. U. S. A. 90:1993;4533-4537